Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of combination CCI-779 [TORISEL; temsirolimus; Wyeth] and bortezomib [VELCADE; Millenium Pharmaceuticals, Johnson and Johnson Pharmaceutical Research and Development LLC] in relapsed and/or relapsed/refractory multiple myeloma

Next Previous
X
Search
Trial Profile

Phase I/II trial of combination CCI-779 [TORISEL; temsirolimus; Wyeth] and bortezomib [VELCADE; Millenium Pharmaceuticals, Johnson and Johnson Pharmaceutical Research and Development LLC] in relapsed and/or relapsed/refractory multiple myeloma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Temsirolimus (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 08 Dec 2010 Results will be presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology
    • 09 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 May 2009 Planned number of patients changed from 31 to 68 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top